Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UNG | P13051 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 10/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958104 | 1.00 | UNG (0.68) | UNGPARP1ERN1TRIM24TRIM33 | |
| SCHEMBL12607521 | 0.89 | ERN1 (0.62) | UNGPARP1ERN1TRIM24TRIM33 | |
| SCHEMBL16950860 | 0.83 | PARP1 (0.55) | UNGPARP1ERN1TSHRPOLB | |
| SCHEMBL6853599 | 0.83 | UNG (0.73) | UNGTRIM24TRIM33TDP1L3MBTL1 | |
| SCHEMBL1515569 | 0.82 | PARP1 (0.50) | UNGPARP1ERN1TSHRPOLB | |
| SCHEMBL5329183 | 0.82 | PARP1 (0.53) | UNGPARP1TSHRPOLBCYP3A4 | |
| SCHEMBL15384461 | 0.82 | UNG (0.61) | UNGPARP1ERN1TRIM24TRIM33 | |
| SCHEMBL30005591 | 0.82 | PARP1 (0.53) | UNGPARP1ERN1TSHRPOLB | |
| SCHEMBL7433812 | 0.82 | UNG (0.60) | UNGALDH1A1 | |
| SCHEMBL2987177 | 0.82 | PARP1 (0.53) | UNGPARP1ERN1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| US-6359061-B1 | COMBINATORIAL LIBRARIES ARE USEFUL FOR SCREENING IN BIOLOGCAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240181438-A1 | UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117866376-A | Polyacetal resin composition | 旭化成株式会社 | 2024-04-12 | — | — | CN | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-1998047875-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 4'-TRIFLUOROMETHYL-BIPHENYL-2-CARBOXYLIC ACID (1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-YL)-AMIDE | PFIZER INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5376685-A | Arylhydrazones using as SAMDC inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | disclosed |
| US-5238941-A | S-adenosylmethionine decarboxylase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0335832-B1 | ARYL HYDRAZONES | CIBA-GEIGY AG (CH) | 1993-02-10 | — | — | EP | disclosed |
| US-5118709-A | Decarboxylase enzyme inhibitors; antitumor agents | CIBA-GEIGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| US-4971986-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
| EP-0335832-A2 | Aryl hydrazones | CIBA-GEIGY AG (CH) | 1989-10-04 | — | — | EP | disclosed |
| CN-86101268-A | The preparation method of new peptidase inhibitors | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | UNG 1146/4885PARP1 1123/4885ERN1 727/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | UNG 1125/4885PARP1 1048/4885ERN1 1534/4885 |
| US-20240181438-A1 | UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME | NDC1, NUDC, NSFL1C | UNG 295/4885PARP1 307/4885ERN1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.